Literature DB >> 19913383

The importance of the DSM-IV E and F criteria in self-report assessments of PTSD.

Adriel Boals1, Lisa M Hathaway.   

Abstract

The purpose of the current study was to examine the DSM-IV E and F criteria when using self-report measures of Posttraumatic Stress Disorder (PTSD). According to DSM-IV there are six core criteria required for a PTSD diagnosis including specific trauma characteristics, re-experiencing, avoidance, hyperarousal, duration, and impairment level. The Impact of Events Scale (IES) is a widely used self-report measure designed to measure PTSD symptoms. It has recently been suggested that the IES may produce misleading results, making emotional reactions to obviously non-traumatic events look like PTSD. In two separate studies, when duration (E criterion) and subjective impairment (F criterion) were included, the rates of those meeting PTSD criteria dropped from 20% to 3%. In addition, only 30% of events identified by a trauma history questionnaire met the DSM-IV definition of a traumatic event. The results have implications for the use of self-report measures in the assessment of PTSD.

Entities:  

Mesh:

Year:  2010        PMID: 19913383     DOI: 10.1016/j.janxdis.2009.10.004

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  3 in total

1.  Elucidating posttraumatic stress symptom profiles and their correlates among women experiencing bidirectional intimate partner violence.

Authors:  Julianne C Hellmuth; Véronique Jaquier; Suzanne C Swan; Tami P Sullivan
Journal:  J Clin Psychol       Date:  2014-04-19

Review 2.  Impact of Sedation on Cognitive Function in Mechanically Ventilated Patients.

Authors:  Jahan Porhomayon; Ali A El-Solh; Ghazaleh Adlparvar; Philippe Jaoude; Nader D Nader
Journal:  Lung       Date:  2015-11-11       Impact factor: 2.584

3.  Effect of cyclooxygenase‑2 inhibition on the development of post‑traumatic stress disorder in rats.

Authors:  Mengyang Wang; Faliang Duan; Jinglei Wu; Qiang Min; Qiaochun Huang; Ming Luo; Zhuqiang He
Journal:  Mol Med Rep       Date:  2018-01-31       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.